Trial Profile

A first-in-man clinical trial of VB 601

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VB-601 (Primary)
Indications Inflammation
Focus Adverse reactions; First in man
Sponsors Notable Labs; VBL Therapeutics

Most Recent Events

14 Nov 2022 According to a VBL Therapeutics media release, the company has filed a regulatory submission to the Israel Ministry of Health and institutional review board to conduct the trial.
14 Nov 2022 According to a VBL Therapeutics media release, the company plans to initiate this trial in the first quarter of 2023, subject to the outcome of the strategic process of the company.
19 Jul 2022 According to a VBL Therapeutics media release, the study is anticipated to start in the fourth quarter of 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com